KFF September 26, 2023
Medicare recently announced the first 10 Part D drugs selected for negotiation under Medicare’s new drug price negotiation program. These drugs were identified as the 10 top spending drugs covered under Medicare Part D without generic or biosimilar equivalents that have been on the market for at least seven years and also meet other selection criteria. The 10 drugs selected for the first round of negotiations include treatments for several medical conditions, including diabetes (Farxiga, Fiasp/NovoLog, Januvia, Jardiance), blood clots (Eliquis, Xarelto), heart failure (Entresto, Farxiga), psoriasis (Stelara, Enbrel), rheumatoid arthritis (Enbrel), Crohn’s disease (Stelara), and blood cancers (Imbruvica) (Appendix Table 1). Between June 2022 and May 2023, 8.3 million Medicare Part D enrollees used one or more of these...
Today's Sponsors
Today's Sponsor